NovaBay Pharmaceuticals (NYSE:NBY) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report issued on Wednesday. The brokerage issued a sell rating on the stock.

NovaBay Pharmaceuticals Trading Up 10.9 %

Shares of NBY stock opened at $0.09 on Wednesday. The company’s fifty day moving average price is $0.12 and its 200-day moving average price is $0.20. The stock has a market cap of $3.23 million, a PE ratio of -0.02 and a beta of 1.97. NovaBay Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $1.28.

NovaBay Pharmaceuticals (NYSE:NBY) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($0.95) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 150.14% and a negative net margin of 65.46%. The business had revenue of $3.73 million during the quarter. On average, sell-side analysts forecast that NovaBay Pharmaceuticals will post -0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NovaBay Pharmaceuticals

A hedge fund recently bought a new stake in NovaBay Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned about 11.01% of NovaBay Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.